EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EPAC2: A new and promising protein for glioma pathogenesis and therapy

Seidu A Richard

Oncology Reviews · 30.04.2020 · 14 (1)

DOI: 10.4081/oncol.2020.446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reviews, online erschienen am 30.04.2020. Verfasst von Seidu A Richard. Beteiligte Einrichtung: Department of Medicine, Princefield University, Ho, Ghana, West Africa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are prime brain cancers which are initiated by malignant modification of neural stem cells, progenitor cells and differentiated glial cells such as astrocyte, oligodendrocyte as well as ependymal cells. Exchange proteins directly activated by cAMP (EPACs) are crucial cyclic adenosine 3’,5’-monophosphate (cAMP)-determined signaling pathways. Cyclic AMP-intermediated signaling events were utilized to transduce protein kinase A (PKA) leading to the detection of EPACs or cAMP-guanine exchange factors (cAMP-GEFs). EPACs have been detected as crucial proteins associated with the pathogenesis of neurological disorders as well as numerous human diseases. EPAC proteins have two isoforms. These isoforms are EPAC1 and EPAC2. EPAC2 also known as Rap guanine nucleotide exchange factor 4 (RAPGEF4) is generally expression in all neurites. Higher EAPC2 levels was detected in the cortex, hippocampus as well as striatum of adult mouse brain. Activation as well as over-secretion of EPAC2 triggers apoptosis in neurons and EPAC-triggered apoptosis was intermediated via the modulation of Bcl-2 interacting member protein (BIM). EPAC2 secretory levels has proven to be more in low-grade clinical glioma than high-grade clinical glioma. This review therefore explores the effects of EPAC2/RAPGEF4 on the pathogenesis of glioma instead of EPAC1 because EPAC2 and not EPAC1 is predominately expressed in the brain. Therefore, EPAC2 is most likely to modulate glioma pathogenesis rather than EPAC1.

Schlagwörter

Stichwörter der Autor:innen

ApoptosisEPAC2RAPGEF4gliomasinhibitionpathogenesis

Autor:innen und Institutionen

  • Department of Medicine, Princefield University, Ho, Ghana, West Africa.

Zitieren

APA

Richard, S. A. (2020). EPAC2: A new and promising protein for glioma pathogenesis and therapy. Oncology Reviews, 14(1). https://doi.org/10.4081/oncol.2020.446

Vancouver

Richard SA. EPAC2: A new and promising protein for glioma pathogenesis and therapy. Oncology Reviews. 2020;14(1). doi:10.4081/oncol.2020.446

BibTeX
@article{Richard2020,
  author = {Richard, Seidu A},
  title = {EPAC2: A new and promising protein for glioma pathogenesis and therapy},
  journal = {Oncology Reviews},
  year = {2020},
  volume = {14},
  number = {1},
  doi = {10.4081/oncol.2020.446}
}
Kostenlos starten →